Pasar al contenido principal

CONDICIONAMIENTO VASOPROTECTOR PARA MEJORAR LA MECANOTRANSDUCCION ENDOTELIAL EN TEJIDOS ENVEJECIDOS: IMPLICACIONES EN REGENERACION HEPATICA

PID2022-137111OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exacerbated atherosclerosis in progeria is prevented by progerin elimination in vascular smooth muscle cells but not endothelial cells

  • Benedicto, Ignacio
  • Carmona, Rosa María
  • Barettino, Ana
  • Espinós-Estévez, Carla
  • Gonzalo, Pilar
  • Nevado, Rosa M.
  • De la Fuente Pérez, Miguel
  • Andrés-Manzano, María J.
  • González-Gómez, Cristina
  • Rolas, Löic
  • Dorado, Beatriz
  • Nourshargh, Sussan
  • Hamczyk, Magda R.
  • Andrés, Vicente
3 p.-2 fig., Hutchinson-Gilford progeria syndrome (HGPS) is a rare disease caused by the expression of progerin, a mutant protein that accelerates aging and precipitates death. Given that atherosclerosis complications are the main cause of death in progeria, here, we investigated whether progerin-induced atherosclerosis is prevented in HGPSrev-Cdh5-CreERT2 and HGPSrev-SM22α-Cre mice with progerin suppression in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), respectively. HGPSrev-Cdh5-CreERT2 mice were undistinguishable from HGPSrev mice with ubiquitous progerin expression, in contrast with the ameliorated progeroid phenotype of HGPSrev-SM22α-Cre mice. To study atherosclerosis, we generated atheroprone mouse models by overexpressing a PCSK9 gain-of-function mutant. While HGPSrev-Cdh5-CreERT2 and HGPSrev mice developed a similar level of excessive atherosclerosis, plaque development in HGPSrev-SM22α-Cre mice was reduced to wild-type levels. Our studies demonstrate that progerin suppression in VSMCs, but not in ECs, prevents exacerbated atherosclerosis in progeroid mice., Work supported by grant PID2022- 141211OB- I00 funded by MICIU/AEI/10.13039/ 501100011033 and ERDF/EU. I.B. was supported by Comunidad de Madrid (2017- T1/BMD- 5247 and 2021- 5A/BMD- 20944) with cofunding from European Structural and Investment Fund, RYC2021- 033805- I (MICIU/AEI/10.13039/501100011033, European Union NextGenerationEU/PRTR), and PID2022- 137111OA- I00 (MICIU/AEI/10.13039/501100011033, ERDF/EU). Salary support to A.B. (BES- 2017- 079705, MICIU/AEI/10.13039/ 501100011033, ESF), C.E.- E. (Fundación “la Caixa”, LCF/BQ/DR19/1170012), R.M.N (Ministerio de Educación, Cultura y Deporte, FPU16/05027), and M.R.H. (MICIU, IJC2019- 040798- I). CNIC is supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (MICIU), Pro-CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020- 001041- S funded by MICIU/AEI/10.13039/501100011033). Generation of anti- progerin antibody funded by Wellcome Trust (098291/Z/12/Z, 221699/Z/20/Z). Microscopy and Dynamic Imaging Unit- CNIC/ICTS- ReDib supported by ICTS- 2018- 04- CNIC- 16 funded by MICIU/AEI/10.13039/501100011033 and ERDF–A way to make Europe, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome

  • Barettino, Ana
  • González-Gómez, Cristina
  • Gonzalo, Pilar
  • Andrés-Manzano, María J.
  • Guerrero, Carlos R.
  • Espinosa, Francisco M.
  • Carmona, Rosa María
  • Blanco, Yaazan
  • Dorado, Beatriz
  • Torroja, Carlos
  • Sánchez-Cabo, Fátima
  • Quintas, Ana
  • Benguría, Alberto
  • Dopazo, Ana
  • García, Ricardo
  • Benedicto, Ignacio
  • Andrés, Vicente
17 p.-8 fig.-1 graph. abst., Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare disease caused by the expression of progerin, an aberrant protein produced by a point mutation in the LMNA gene. HGPS patients show accelerated aging and die prematurely mainly from complications of atherosclerosis such as myocardial infarction, heart failure, or stroke. However, the mechanisms underlying HGPS vascular pathology remain ill defined. We used single-cell RNA sequencing to characterize the aorta in progerin-expressing LmnaG609G/G609G mice and wild-type controls, with a special focus on endothelial cells (ECs). HGPS ECs showed gene expression changes associated with extracellular matrix alterations, increased leukocyte extravasation, and activation of the yes-associated protein 1/transcriptional activator with PDZ-binding domain (YAP/TAZ) mechanosensing pathway, all validated by different techniques. Atomic force microscopy experiments demonstrated stiffer subendothelial extracellular matrix in progeroid aortas, and ultrasound assessment of live HGPS mice revealed disturbed aortic blood flow, both key inducers of the YAP/TAZ pathway in ECs. YAP/TAZ inhibition with verteporfin reduced leukocyte accumulation in the aortic intimal layer and decreased atherosclerosis burden in progeroid mice. Our findings identify endothelial YAP/TAZ signaling as a key mechanism of HGPS vascular disease and open a new avenue for the development of YAP/TAZ targeting drugs to ameliorate progerin-induced atherosclerosis., This study was supported by grants to V.A. from the Spanish Ministerio de Ciencia,Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI) (MICIU/AEI/10.13039/501100011033 grant PID2019-108489RB-I00), with cofunding from Fondo Social Europeo (FSE) (“El FSE invierte en tu futuro”), and a donation from Asociación Progeria Alexandra Peraut. I.B. was supported by Comunidad Autónoma de Madrid (grants 2017-T1/BMD-5247 and 2021-5A/BMD-20944) with co-funding from the European Structural and Investment Fund, a Ramón y Cajal contract (RYC2021-033805-I) funded by MICIU AEI/10.13039/501100011033 and European Union “NextGenerationEU”/PRTR, and grant PID2022-137111OA-I00 (MICIU/AEI/10.13039/501100011033, ERDF/EU). A. Barettino was supported by predoctoral contract BES-2017-079705 (MICIU/AEI/10.13039/501100011033 and FSE “El FSE invierte en tu futuro”). R.G. was supported by grants PID2019-106801GB-I00/AEI/10.13039/501100011033 and S2018/NMT-4443 (Tec4Bio-CM).The Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) is supported by the MICIU, the Instituto de Salud Carlos III, the Pro-CNIC Foundation,and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endothelial cell-specific progerin expression does not cause cardiovascular alterations and premature death

  • Benedicto, Ignacio
  • Hamczyk, Magda R.
  • Nevado, Rosa M.
  • Barettino, Ana
  • Carmona, Rosa María
  • Espinós-Estévez, Carla
  • Gonzalo, Pilar
  • De la Fuente Pérez, Miguel
  • Andrés-Manzano, María J.
  • González-Gómez, Cristina
  • Dorado, Beatriz
  • Andrés, Vicente
14 p.-6 fig., Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by a mutation in the LMNA gene that provokes the synthesis of progerin, a mutant version of the nuclear protein lamin A that accelerates aging and precipitates death. The most clinically relevant feature of HGPS is the development of cardiac anomalies and severe vascular alterations, including massive loss of vascular smooth muscle cells, increased fibrosis, and generalized atherosclerosis. However, it is unclear if progerin expression in endothelial cells (ECs) causes the cardiovascular manifestations of HGPS. To tackle this question, we generated atherosclerosis-free mice (LmnaLCS/LCSCdh5-CreERT2) and atheroprone mice (Apoe−/−LmnaLCS/LCSCdh5-CreERT2) with EC-specific progerin expression. Like progerin-free controls, LmnaLCS/LCSCdh5-CreERT2 mice did not develop heart fibrosis or cardiac electrical and functional alterations, and had normal vascular structure, body weight, and lifespan. Similarly, atheroprone Apoe−/−LmnaLCS/LCSCdh5-CreERT2 mice showed no alteration in body weight or lifespan versus Apoe−/−LmnaLCS/LCS controls and did not develop vascular alterations or aggravated atherosclerosis. Our results indicate that progerin expression in ECs is not sufficient to cause the cardiovascular phenotype and premature death associated with progeria., Work supported by grant PID2022-141211OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU to V.A. I.B. was supported by the Comunidad de Madrid (2017-T1/BMD-5247, 2021-5A/BMD-20944) with co-funding from the European Structural and Investment Fund, RYC2021-033805-I (MICIU/AEI/10.13039/501100011033, European Union NextGenerationEU/PRTR), and PID2022-137111OA-I00 (MICIU/AEI/10.13039/501100011033, ERDF/EU). A.B. was supported by MICIU/AEI/10.13039/501100011033 and ESF (BES-2017-079705); C.E.-E. by Fundación “la Caixa” (LCF/BQ/DR19/1170012), R.M.N by the Ministerio de Educación, Cultura y Deporte (FPU16/05027), and M.R.H. by the MICIU (IJC2019-040798-I), AIAS and Aarhus University Research Foundation. The CNIC is supported by Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades (MICIU), and Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). Microscopy was conducted at the CNIC Microscopy Unit and ICTS (Unique Science and Technology Infrastructure)-ReDiB supported by MICIU at TRIMA (MICIU/AEI/10.13039/501100011033 and the ERDF, A way to make Europe)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vascular cell types in progeria: victims or villains?

  • Benedicto, Ignacio
  • Hamczyk, Magda R.
  • Dorado, Beatriz
  • Andrés, Vicente
35 p.-1 fig.-1 tab., Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare genetic disease caused by progerin, a broadly expressed mutant variant of lamin A protein that accelerates aging and leads to premature death typically in adolescence. Progerin affects many organs and reproduces many characteristics of physiological aging, with the main cause of death in HGPS being atherosclerotic cardiovascular disease (CVD). Due to the rarity of HGPS, advances in understanding the disease and progress toward new therapeutic approaches are crucially dependent on preclinical models. We discuss recent research developments from a variety of HGPS experimental systems, with a special focus on in vivo studies of the role of vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) that are key players in atherosclerosis., The laboratory of V.A. is supported by the Spanish Ministry of Science, Innovation, and Universities (MICIU; PID2022-141211OB-I00, MICIU/AEI/10.13039/501100011033) with cofunding from the European Regional Development Fund (ERDF), European Joint Programme on Rare Diseases (EJPRD22-049), and Instituto de Salud Carlos III (ISCIII) (AC22/00020), Fundación Ramón Areces (CIVP21A7006), Fundación Marató TV3 (202033-31), and donations from the Asociación Progeria Alexandra Peraut and Fundación Inocente. I.B. is supported by grants RYC2021-033805-I (MICIU/AEI/10.13039/501100011033, EU NextGenerationEU/PRTR) and PID2022-137111OA-I00 (MICIU/AEI/10.13039/501100011033, ERDF/EU). M.R.H. is supported by AIAS and Aarhus University Research Foundation. The CNIC is supported by the ISCIII, the MICIU, and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033)., Peer reviewed